MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11060-025-05160-4

Медицинская библиотека · Journal of neuro-oncology · 2025

Intrathecal pemetrexed for newly diagnosed leptomeningeal metastases: a multicenter, open-label, phase I/II study.

Pan Zhenyu, Ye Xiaojun, Huang Yushan, Tai Panpan, Liu Miaomiao, Sun Xingru, Tang Ran, Gu Anyan, Wang Zhuo, Shen Longhai, Pang Xiaochuan, Yuan Tingting, Yang Guozi

СтатьяКлиническое исследование I фазыКлиническое исследование II фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: This phase I/II study aimed to determine the maximum-tolerated dose (MTD) of intrathecal pemetrexed (IP) with vitamin supplementation, and to evaluate its safety, feasibility and therapeutic activity for newly diagnosed leptomeningeal metastasis (LM) from solid tumors.

METHODS

The phase I study followed the classic 3 + 3 design, with IP dose escalating from 15 mg. The recommended dose was applied in the phase II study. IP was administered first as induction therapy twice weekly for 2 weeks, followed by consolidation therapy, once weekly for 4 weeks, then maintenance therapy once monthly. Vitamin supplementation was initiated prior to the first IP dose. The MTD, adverse events (AEs), overall survival (OS), clinical response rate (CRR) and disease control rate (DCR) were evaluated.

RESULTS

A total of 34 patients were enrolled. In the phase I study, 2 patients in the 20 mg group experienced dose-limiting toxicity, including grade 4 leukopenia and grade 5 chemical arachnoiditis. The MTD was established as 15 mg. Among 28 patients in the MTD group, 24 completed induction therapy, 19 completed consolidation therapy and 11 proceeded to maintenance therapy. The overall AEs rate was 74% (25/34), and severe AEs rate (> grade 3) was 15% (5/34). In the MTD group, the CRR, DCR and median OS were 46% (13/28), 75% (21/28) and 8.1 months (95% CI, 6.5-11.9).

CONCLUSION

IP at 15 mg, with folic acid and vitamin B12 supplementation initiated before the first IP dose, demonstrated feasibility and exhibited controllable toxicity. This regimen offers a new treatment option with therapeutic activity for newly diagnosed LM patients with solid tumors.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT05289908.

Для цитирования: Pan Zhenyu, Ye Xiaojun, Huang Yushan, Tai Panpan, Liu Miaomiao, Sun Xingru, Tang Ran, Gu Anyan, Wang Zhuo, Shen Longhai, Pang Xiaochuan, Yuan Tingting, Yang Guozi. Intrathecal pemetrexed for newly diagnosed leptomeningeal metastases: a multicenter, open-label, phase I/II study.. Journal of neuro-oncology. 2025. DOI: 10.1007/s11060-025-05160-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.